Table 2 The use of systematic reviews in trial design
From: Using systematic reviews to inform NIHR HTA trial planning and design: a retrospective cohort
Reasons | Cohort I No. of applications (%) | Cohort II No. of applications (%) |
|---|---|---|
(n = 42) | (n = 34) | |
Adverse events | 7 (16.6) | 1 (2.9) |
Choice of frequency/dose | 2 (4.7) | 1 (2.9) |
Duration of follow-up | 1 (2.3) | 2 (5.8) |
Estimating the control group event rate | 2 (4.7) | 0 (0) |
Estimating the difference to detect or margin of equivalence | 2 (4.7) | 1 (2.9) |
Inform standard deviation | 0 (0) | 3 (8.8) |
Intensity of interventions | 1 (2.3) | 1 (2.9) |
Justification of prevalence | 3 (7.1) | 0 (0) |
Justification of treatment comparison | 38 (90.4) | 32 (94.1) |
Recruitment and consent | 4 (9.5) | 1 (2.9) |
Route of intervention | 0 (0) | 1 (2.9) |
Selection of definition or outcome | 5 (11.9) | 5 (16.1) |
Withdrawal rate | 1 (2.3) | 0 (0) |